Alternative Income Fund
| Mandate | Canadian Multi Strategy |
| Inception Date: | January 22, 2019 |
| Fund Codes: | Class F NEW401 USD: NEW401U Class G NEW403 USD: NEW403U |
| Management Fees: | Class F 1% Class G 2% |
| Performance Fee | 15% |
| Liquidity | Daily |
Simplified Prospectus
2022Simplified Prospectus (ENG) Simplified Prospectus (FRE)
Summary of Investment Portfolio
2022Summary of Investment Portfolio Q1
Fund Fact Sheet
2022NewGen Alternative Income Fund – Class F
Management Report of Fund Performance
2021Interim Management Report of Fund Performance (ENG) Interim Management Report of Fund Performance (FRE) Management Report of Fund Performance (ENG) Management Report of Fund Performance (FRE)
Financial Statements
2021Interim Financial Statements June 30 2021 (ENG) Interim Financial Statements June 30 2021 (FRE) Audited Financial Statements Dec 31 2021 (ENG) Audited Financial Statements Dec 31 2021 (FRE) 2020
Audited Financial Statements Dec 31 2020 (ENG) Audited Financial Statements Dec 31 2020 (FRE) Interim Financial Statements June 30 2020 (ENG) Interim Financial Statements June 30 2020 (FRE)
The NewGen Alternative Income Fund was launched in January 2019 under Canada’s new “Liquid Alternatives” regulatory framework; i.e. a hedge fund strategy available to retail investors through a prospectus offering. The Fund provides investors with exposure to (1) an actively managed diversified portfolio of dividend/income paying securities with a target portfolio yield of 4-5% (paid monthly); (2) a portfolio of stock-specific Alpha shorts to generate additional return and preserve capital by reducing market Beta; and (3) a multi-strategy overlay that relies on a broad range of strategies and securities in order to enhance yield, generate Alpha, and provide additional diversification benefits to our investors.
The NewGen Alternative Income Fund is offered to Canadian Investors only. US and other
international investors are not eligible.
NewGen Alternative Income Fund: Growth of $10,000 Since Inception
NewGen Alternative Income Fund
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | YTD | ||
| 2019 | NG Alt Inc | 4.06% | 4.91% | 0.76% | 0.13% | -0.75% | 1.36% | -1.10% | -0.86% | -1.39% | -1.32% | 2.01% | 1.30% | 9.23% |
| S&P/TSX | 1.34% | 3.15% | 1.01% | 3.22% | -3.06% | 2.53% | 0.34% | 0.43% | 1.69% | -0.86% | 3.59% | 0.45% | 14.52% | |
| 2020 | NG Alt Inc | 1.25% | -3.16% | -7.53% | 5.38% | 2.81% | 0.91% | 3.62% | 2.66% | -1.36% | 0.50% | 4.41% | 4.40% | 13.93% |
| S&P/TSX | 1.74% | -5.90% | -17.38% | 10.79% | 3.04% | 2.46% | 4.48% | 2.35% | -2.06% | -3.11% | 10.57% | 1.72% | 5.60% | |
| 2021 | NG Alt Inc | 2.10% | 2.19% | 1.52% | 1.53% | 0.49% | 0.84% | -0.74% | 1.81% | -0.42% | 1.81% | -2.16% | 0.68% | 9.98% |
| S&P/TSX | -0.32% | 4.36% | 3.87% | 2.39% | 3.44% | 2.48% | 0.80% | 1.63% | -2.22% | 5.02% | -1.62% | 3.06% | 25.09% | |
| 2022 | NG Alt Inc | -1.15% | 1.34% | 0.85% | -1.49% | 1.29% | -3.09% | -2.32% | ||||||
| S&P/TSX | -0.41% | 0.28% | 3.96% | -4.96% | 0.06% | -8.71% | -9.87% |
| 1-MTH | YTD | 1 -YR | 3-YR | 5-YR | INCEPTION |
| -3.09% | -2.32% | -1.40% | 6.46% | n/a | 8.65% |
The NewGen Alternative Income Fund began trading on January 22nd, 2019 – performance for the month reflects that.
Fund returns are presented net of fees and assume that monthly distirbutions are reinvested
The TSX Total Return Index comparative performance is provided for illustrative purposes only – it is a widely followed index but is not considered a benchmark due to differing holding composition compared to the NewGen Alternative Income Fund. The composition of the Funds’ portfolio could differ significantly from the index due to the investment strategy employed, and includes differences such as use of short positions, varying fund net exposure, varying sector exposure, and investing in small and mid capitalization stocks. Please see “Investment Strategies” in the Confidential Offering Memorandum for more details.
Jensen’s Alpha is a hypothetical measures of excess return (a risk-free rate of 1.5% is assumed)